15.75
-0.3(-1.87%)
Currency In USD
| Previous Close | 16.05 |
| Open | 16.29 |
| Day High | 16.73 |
| Day Low | 15.07 |
| 52-Week High | 26.25 |
| 52-Week Low | 5.83 |
| Volume | 113,631 |
| Average Volume | 175,078 |
| Market Cap | 658.89M |
| PE | -4.05 |
| EPS | -3.89 |
| Moving Average 50 Days | 11.35 |
| Moving Average 200 Days | 11.09 |
| Change | -0.3 |
If you invested $1000 in ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) since IPO date, it would be worth $876.46 as of July 30, 2025 at a share price of $15.75. Whereas If you bought $1000 worth of ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) shares 0 years ago, it would be worth $876.46 as of July 30, 2025 at a share price of $15.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 20, 2025 8:15 PM GMT
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies f
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 11:05 AM GMT
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies fo
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Apr 17, 2025 8:20 PM GMT
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies